Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Wednesday, June 24, 2026

Snapshot: Jun 24, 2026 · 6:00 PM 100 stocks analyzed

Strong Down Day

Wed, Jun 24, 2026 Divergent High

Nasdaq plunged 3.4% and Russell 2000 surged 1.6% in a sharp divergence as tech sold off hard while small caps rallied, with extreme dispersion across 50 gainers averaging +26% a…

55% The market regime fractured sharply: S&P 500 dropped 2.04%, Nasdaq Composite crashed 3.41%, but Russell 2000 jumped 1.64%, marking a classic value rotation away from mega-cap tech into small-cap equities. VIX spiked 13.6% to signal rising fear, yet the divergence between index moves suggests tactical money rotation rather than broad-based panic.
30% Dispersion hit extremes with 50 gainers averaging +26.0% (topped by SCAG at +101%) and 50 losers averaging -22.6% (led by ATLN at -41%), meaning individual stock moves dwarfed index moves. News-grounded catalysts included PLSM (+93% on Ouma partnership), ICCM (+52% on cryoablation data), NVCT (+39% on $1.4B Haisco deal), and a wave of 5 debutants surging back into the top-50 gainers list.
15% Financial Services dominated the losers with 33% of the 50-stock list, while Healthcare led gainers at 27%, suggesting sector-level rotation. ATLN's collapse to -41% after surging 150% the prior day exemplified profit-taking, while news-driven losses like HTZ (-41% on earnings miss) and HYLN (-19% on short-seller fraud allegations) underscored headline-driven selling in the broader downturn.

Financial Services drove 33% of losers 5 names returned after long absences JLHL · 3-day losers streak VTAK — first appearance SLN — first appearance

Market Regime

Wed, Jun 24, 2026 Neutral conf: low macro · prototype

Neutral −100 … +100 · + tailwind / − headwind

VIX18.6 Drawdown-3.3% Held4d · building SinceJun 19

Top drivers: Small-cap leadership ▲ S&P vs 20d avg ▼ S&P 20d return ▼

processId: history-market-regime

Market Indexes

Wed, Jun 24, 2026 13

S&P 500

7,358.22

−153.13

-2.04%

Dow Jones

51,848.90

−150.77

-0.29%

NASDAQ Composite

25,476.64

−899.71

-3.41%

NASDAQ 100

29,220.06

−748.07

-2.50%

DJ US Total Market

73,072.44

−1,327.31

-1.78%

Russell 1000

4,009.62

−77.88

-1.91%

S&P MidCap 400

3,788.61

−7.32

-0.19%

Russell 2000

2,986.63

+47.43

+1.61%

Russell 2500

1,262.85

+5.00

+0.40%

Russell 3000

4,192.65

−74.23

-1.74%

Nasdaq Financial-100

7,098.73

−135.42

-1.87%

NIFTY 50

24,021.65

−146.35

-0.61%

VIX

18.63

+2.23

+13.60%

Biggest Gainers

Wed, Jun 24, 2026 50

SCAG

Scage FutureIndustrials

$0.71+$0.36

+101.0%

NASDAQ · Mkt cap $22 M

No news headlines were found in the last 48 hours, so the 101% gain cannot be attributed to a specific announced event. The move is most likely driven by technical factors, short covering, or undisclosed market rumors.

Scage Future (SCAG) doubled in a single day with zero identified news catalyst in the provided sources. This is a microcap penny stock trading at $0.71, which makes it highly susceptible to technical rallies, short squeezes, retail speculation, and low-volume momentum trades. Without headlines pointing to earnings, clinical data, partnerships, or guidance changes, the move appears detached from fundamental news flow. Penny stocks of this liquidity profile can experience explosive intraday rallies on minimal volume or social media attention. The absence of news does not rule out a legitimate corporate announcement that simply did not reach Yahoo Finance's RSS feed within the 48-hour window, but we cannot confirm that here.

PLSM

Pulsenmore Ltd. Ordinary SharesHealthcare

$6.59+$3.18

+93.3%

NASDAQ · Mkt cap $20 M

Pulsenmore announced a strategic partnership with Ouma Health, the largest U.S. maternity telemedicine company, to deploy its home ultrasound platform, a major commercial validation that drove the stock surge.

On June 24, 2026, Pulsenmore announced a partnership with Ouma Health to integrate its home ultrasound technology into Ouma's virtual prenatal care offerings across the United States. This represents a concrete commercial win with a named, leading partner in a large addressable market (maternity care). The partnership validates Pulsenmore's core product offering by securing adoption from a major telemedicine player, which typically signals revenue potential and market traction for medtech platforms. The stock surged over 93 percent on the day, with one headline citing a gain exceeding 200 percent at intraday peak, suggesting strong institutional and retail enthusiasm around the growth opportunity. The partnership is material news for a company focused on expanding remote healthcare access through home ultrasound technology.

SKYQ

Sky Quarry Inc.Energy

$2.62+$0.98

+59.8%

NASDAQ · Mkt cap $12 M

No news headlines were found in the last 48 hours, so the 59.76% gain cannot be attributed to a disclosed catalyst. The jump likely reflects technical trading, delayed news dissemination, or undisclosed market events.

Sky Quarry Inc. experienced a major single-day rally with no corresponding financial news in the available sources. This disconnect is notable and suggests several non-headline possibilities. The stock could be responding to a press release or announcement that has not yet propagated to the Yahoo Finance RSS feed used here, or to technical factors such as short covering, options-related gamma activity, or renewed retail interest. Small-cap stocks like those on NASDAQ frequently experience outsized moves on modest volume without immediate news visibility. Without access to company filings, insider activity, or real-time social media sentiment, the specific driver remains opaque. The move warrants verification through the company's investor relations channels or direct news sources.

ICCM

IceCure Medical LtdHealthcare

$9.30+$3.18

+52.0%

NASDAQ · Mkt cap $8.6 M

IceCure Medical surged 52% on publication of a peer-reviewed journal article demonstrating that its cryoablation technology outperforms radiofrequency ablation for early-stage breast cancer treatment, validating its clinical efficacy and competitive advantage.

The company released news on June 23 highlighting a new peer-reviewed article in a leading surgery journal showing cryoablation's superiority over radiofrequency ablation for early-stage breast cancer. For a medical device company, publication of favorable clinical data in a high-impact journal is a significant catalyst, as it provides third-party validation of efficacy, strengthens marketing claims, supports future regulatory submissions, and may drive physician adoption. The timing of the stock surge the following day aligns directly with the announcement. This is a clinically focused narrative that appeals to institutional investors seeking evidence of competitive differentiation in the minimally-invasive ablation market. The magnitude of the gain (52%) suggests either the market had previously discounted the company's prospects or the journal's reputation and the study results exceeded expectations.

STFS

Star Fashion Culture Holdings LimitedCommunication Services

$12.84+$4.39

+52.0%

NASDAQ · Mkt cap $5.3 M

No news headlines were found in the last 48 hours, so the cause of STFS's 51.95% gain cannot be identified from reported events. The jump likely reflects technical trading, short-covering, or undisclosed company developments.

The absence of news in the Yahoo Finance RSS feed over the past two days means we cannot attribute this significant move to a specific catalyst like earnings, guidance, or corporate action. A 52% single-day jump is substantial and typically warrants news coverage if driven by material company developments. For a fashion culture stock of this size, possible explanations include short squeeze dynamics if the stock has high short interest, a delayed or untracked announcement not yet indexed by major news feeds, retail trading momentum on social media, technical breakout, or sector-wide tailwinds in fashion retail. Without access to short interest data, company filings, or real-time social sentiment, only generic categories can be offered rather than a concrete catalyst.

CUPR

Cuprina Holdings (Cayman) Limited Class A Ordinary SharesHealthcare

$5.74+$1.80

+45.7%

NASDAQ · Mkt cap $8.0 M

No news headlines were found in the last 48 hours, so the 45.69% gain cannot be attributed to a specific disclosed event; the move likely reflects technical trading, delayed news dissemination, or undisclosed catalysts.

The absence of recent news headlines makes it impossible to identify a concrete catalyst for CUPR's substantial single-day gain of 45.69%. For a lower-priced NASDAQ stock like this, significant moves without visible news often stem from technical factors such as short covering, options-related gamma effects, or accumulation by retail traders following social media discussion. Alternatively, company news may have been released through channels not captured in the Yahoo Finance RSS feed, or the stock may be responding to sector-wide momentum, analyst upgrades, or insider activity that has not yet reached mainstream financial media. Without access to press releases, SEC filings, or direct company communications, identifying the specific cause remains speculative.

NVCT

Nuvectis Pharma, Inc.Healthcare

$24.48+$6.93

+39.5%

BOXL

Boxlight CorporationTechnology

$4.88+$1.32

+37.1%

NASDAQ · Mkt cap $3.5 M

No news headlines were published in the last 48 hours for Boxlight, so the 37% jump on June 24 cannot be directly attributed to a company announcement. The move likely reflects either technical trading, delayed market reaction to earlier news, or unconfirmed rumors.

The absence of recent news headlines makes it impossible to tie the sharp gain to a specific catalyst like earnings, product wins, or strategic announcements. Boxlight is a small-cap education technology company that historically experiences elevated volatility. For stocks in this category, large single-day moves without concurrent news often stem from a few sources: short covering or technical breakout (common for lower-priced stocks), delayed market reaction to news released before the 48-hour window, options-related hedging dynamics, or unconfirmed social media or message board activity that spreads awareness but doesn't appear in mainstream headlines. Without visibility into trading data, insider activity, or confirmatory news, pinpointing the exact cause requires guesswork rather than evidence.

ABSI

Absci CorporationHealthcare

$10.08+$2.67

+36.0%

NASDAQ · Mkt cap $1.5 B

Absci surged 36% on positive Phase 1 hair loss drug data for ABS-201 showing good tolerability and long half-life, combined with a $100M strategic funding round led by Eli Lilly and major institutional investors announced the same day.

The headline evidence points to a coordinated positive catalyst on June 24th. Absci announced interim Phase 1 safety results for ABS-201 that were favorable across multiple dosing cohorts, with an estimated half-life of at least 65 days supporting potential for convenient dosing intervals. Simultaneously, the company priced a $100M underwritten offering with participation from Eli Lilly, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile and others, signaling strong institutional confidence in both the asset and management. The market appears to have responded to the combination of de-risked clinical data and substantial capital injection from tier-one investors. Additionally, Guggenheim had recently raised its price target from $10 to $15 on June 15th, providing a bullish research backdrop. These three elements together—positive clinical data, major funding, and prior analyst upgrade—explain the magnitude of the single-day gain.

RIBBR

Ribbon Acquisition Corp.

$0.24+$0.05

+29.8%

NASDAQ · Mkt cap $1.2 M

No news headlines were reported in the last 48 hours, so the 29.83% gain cannot be attributed to a specific company announcement or market catalyst. The move likely reflects technical trading, short covering, or a delayed news event not yet indexed in the available feed.

Ribbon Acquisition Corp. is a special purpose acquisition company (SPAC) trading at a very low price of $0.24, which makes it highly sensitive to volume shifts and speculative positioning. With no news provided in the past 48 hours, the sharp one-day jump cannot be tied to earnings, a merger announcement, or corporate action. SPACs at this price level and stage often experience volatile moves driven by technical factors such as short squeezes, thin liquidity amplifying small volume spikes, or accumulation by retail traders. It is also possible that a news event occurred but has not yet propagated to the headline feed, or that the gain reflects delayed market reaction to an earlier announcement.

FMFC

Kandal M Venture LimitedConsumer Cyclical

$0.32+$0.07

+29.6%

NASDAQ · Mkt cap $4.1 M

No news headlines were found in the last 48 hours, so the 29.6% gain likely reflects technical trading activity, delayed news dissemination, or market microstructure effects in a low-liquidity micro-cap stock.

Kandal M Venture Limited is a very small-cap NASDAQ-listed entity with no recent news coverage available through the Yahoo Finance feed. A 29.6% single-day move in a stock priced at $0.32 is not uncommon for micro-cap securities, which often experience outsized swings on low volume, short-covering, or retail attention. Without news anchors, the most probable explanations are technical in nature: a squeeze of short positions, algorithmic or momentum-based buying, delayed disclosure of an earnings release or corporate action elsewhere, or simply a thin order book amplifying modest volume. The absence of headlines does not rule out a real catalyst having occurred; it may reflect delays in news aggregation or the event posting on non-mainstream channels.

VTAK

Catheter Precision, Inc.Healthcare

$1.19+$0.27

+29.3%

AMEX · Mkt cap $770 K

A 29% surge in VTAK on June 24 cannot be directly attributed to the two headlines provided, as one concerns Creatd (an unrelated company) and the other involves Flyte, a different entity. The move likely stems from unreported news, technical factors, or market microstructure specific to this micr…

The two news items in the feed do not pertain to Catheter Precision, Inc. (VTAK). The Creatd filing and the Flyte-GSE Worldwide partnership announcement are separate companies entirely and provide no actionable information about VTAK's fundamentals or catalysts. For a micro-cap stock trading at $1.19 on AMEX, large single-day percentage moves are not uncommon and can result from several sources: a private placement or financing announcement, clinical trial data or regulatory feedback, sector rotation into medical devices, short covering or technical momentum, or simply low liquidity amplifying modest share volume. Without access to VTAK-specific headlines on or immediately before June 24, it is impossible to pinpoint the trigger with confidence.

MGN

Megan Holdings Limited Ordinary SharesIndustrials

$0.22+$0.05

+26.7%

NASDAQ · Mkt cap $3.7 M

No news was found in the last 48 hours to explain MGN's 26.7% gain, so the driver remains unclear and could be technical, a delayed announcement, or retail trading activity.

Yahoo Finance returned zero headlines for Megan Holdings Limited in the last 48 hours, which creates a clear gap between the stock's strong upward move and any identifiable catalyst. MGN is a micro-cap trading at $0.22, a security class typically prone to technical bounces, short covering, rumor-driven retail flows, or delayed dissemination of news across wire services. Without confirmation of earnings, guidance, partnerships, or other corporate events, the most likely categories are either a technical rebound after oversold conditions, covering of a short position, or news that has not yet appeared in the Yahoo Finance feed. The stock's rank as the 13th biggest gainer suggests broad-based momentum rather than single-stock news, but that remains inference rather than fact.

SLN

Silence Therapeutics plcHealthcare

$9.16+$1.89

+26.0%

NASDAQ · Mkt cap $919 M

No material news about Silence Therapeutics was provided; the 26% gain occurred on a day when European ADRs traded lower overall, suggesting the jump may reflect a short squeeze, technical rebound, or undisclosed company-specific catalyst.

The headline provided is a market-wide statement that European equities traded as ADRs declined on Wednesday, which is actually contrary to SLN's strong outperformance. This suggests the broad ADR weakness did not drive SLN higher. No company-specific news, clinical data, partnership announcements, or regulatory developments are mentioned in the available headlines. For a small-cap biotech like Silence Therapeutics, a 26% single-day jump typically correlates with clinical trial results, FDA communications, licensing deals, or capital announcements. Without such news in the record, the move likely reflects either technical factors such as short covering or a delayed market reaction to an announcement not yet captured in the provided headlines. The ranking as the 14th biggest gainer suggests this was a broad market observation, but the mechanism remains opaque.

WEN

The Wendy's CompanyConsumer Cyclical

$7.86+$1.61

+25.7%

NASDAQ · Mkt cap $1.5 B

Wendy's surged 25.66% after a CFO leadership change triggered meme stock momentum on Reddit and WallStreetBets, with retail traders piling into the heavily shorted stock on hopes of a turnaround and potential short squeeze.

The headline evidence is clear and consistent: on June 24, 2026, Wendy's announced a new CFO (Steve Cirulis), which catalyzed viral Reddit activity, particularly a post titled "We need to save Wendy's" on WallStreetBets. Multiple sources confirm that retail traders interpreted the leadership change as a turnaround signal and began accumulating shares in what observers explicitly labeled a meme stock rally. The stock trades heavily short, making it structurally vulnerable to a squeeze when buy pressure accelerates. The intraday high was reported near 42%, though the closing price reflects a 25.66% gain. News sources attribute the move directly to the CFO appointment combined with social media hype rather than operational earnings or strategic announcements about the business itself.

GALT

Galectin Therapeutics Inc.Healthcare

$3.92+$0.80

+25.6%

NASDAQ · Mkt cap $355 M

Galectin jumped 25% after the FDA cleared a regulatory pathway for belapectin's Phase III trial in MASH cirrhosis, with agreement on the primary endpoint and a Q3 2026 protocol filing planned.

The stock's sharp gain is grounded in a concrete FDA development. Over the 48-hour window, Galectin announced a positive Type C meeting with the FDA regarding belapectin in MASH cirrhosis patients with portal hypertension. The key catalysts were regulatory alignment on the primary endpoint and a defined path to full approval. The company will submit its Phase III protocol in Q3 2026. For a clinical-stage biopharma company, FDA clarity on trial design and approval pathway significantly de-risks the development program and improves the probability of eventual commercialization, which directly justifies investor enthusiasm. This is a straightforward regulatory milestone event typical of how small-cap biotech companies move on late-stage trial validation.

DOMO

Domo, Inc.Technology

$2.75+$0.51

+22.8%

NASDAQ · Mkt cap $176 M

No news headline directly explains DOMO's 22.77% surge today. The most recent headlines from the past 48 hours describe sector-wide weakness in software and communication services, which contradicts the positive move.

The available headlines present a puzzle. On June 22, DOMO was mentioned alongside DigitalOcean in a piece about broader sector selloffs triggered by AI talent departures from Alphabet and regulatory concerns affecting software and communication-services stocks. That context would normally predict downside pressure, yet DOMO rallied sharply on June 24. The June 23 headline about Wall Street's favorite stocks and analyst skepticism is too generic to identify a specific catalyst. No earnings release, guidance revision, partnership announcement, or company-specific news appears in the provided feed. The move may reflect a technical rebound after oversold conditions, short covering, options-related activity, or an announcement not yet captured in this news feed. Without direct evidence of a triggering event, the cause remains speculative.

WKSP

Worksport Ltd.Consumer Cyclical

$1.03+$0.19

+22.6%

NASDAQ · Mkt cap $9.8 M

No news headlines were found in the last 48 hours, so the 22.62% gain cannot be tied to a specific announced catalyst; the move may reflect technical trading, delayed news dissemination, or retail interest in a low-priced stock.

Worksport is a micro-cap security trading below $1.10, which typically exhibits higher volatility and can be sensitive to retail trading activity, short covering, or delayed news propagation. The absence of recent Yahoo Finance headlines does not rule out a real catalyst—news may have been released through other channels, embargo lifts, or company announcements not yet indexed by the feed. Alternatively, the move could reflect technical momentum in a stock with thin liquidity, options expiration effects, or sector rotation into small-cap equity names. Without headlines directly tied to earnings, product announcements, partnerships, or guidance changes, we cannot identify a specific event driver from the information provided.

UBXG

U-BX Technology Ltd.Communication Services

$8.49+$1.55

+22.3%

NASDAQ · Mkt cap $11 M

No news headlines were found in the last 48 hours for UBXG, so the 22.33% gain likely reflects technical trading activity, delayed news pickup, or a company-specific catalyst not yet indexed by the major financial RSS feeds.

The absence of recent headlines in the Yahoo Finance RSS feed creates a clear data gap. A 22.33% single-day move is substantial and would typically be associated with material news such as earnings results, strategic announcements, guidance changes, or sector-wide catalysts. For a small-cap NASDAQ stock like UBXG, common drivers of outsized gains include short covering, options-related technical moves, insider transactions becoming public, or acquisition rumors circulating on social media or industry channels before formal wire distribution. Another possibility is that the news broke outside the 48-hour window captured here, or the story is moving through less mainstream channels. Without access to company filings, social media activity, or trading volume data, we cannot distinguish between these scenarios. The lack of evidence should prompt skepticism about attributing this move to any specific fundamental catalyst.

NWGL

CL Workshop Group LimitedBasic Materials

$0.27+$0.05

+21.8%

NASDAQ · Mkt cap $4.6 M

No news headlines were found in the last 48 hours for NWGL, so the 21.77% gain cannot be attributed to any disclosed event; the move likely reflects technical trading, retail interest, or an unannounced development not yet in major news feeds.

The absence of any news in the Yahoo Finance RSS feed over the past 48 hours means we cannot point to a specific catalyst such as earnings, guidance, partnerships, or regulatory actions. For a micro-cap stock trading at $0.27, price moves of this magnitude are not uncommon and can reflect multiple drivers: algorithmic trading, short covering, retail social media activity, or delayed disclosure of material information that has not yet reached mainstream financial news. Without access to company filings, press releases, or trading data showing unusual volume or short interest, it is impossible to distinguish between legitimate news and purely technical or sentiment-driven movement. The ranking as the 20th biggest gainer suggests broad participation but does not clarify intent.

RKLZ

DEFIANCE DAILY TARGET 2X SHORT RKLB ETF

$4.01+$0.69

+20.8%

NASDAQ

No news headlines were found in the last 48 hours, but RKLZ is a 2X short leveraged ETF tracking Rocket Lab (RKLB), so a 20.78% gain likely reflects a sharp drop in RKLB stock price amplified by the leveraged structure.

RKLZ is the Defiance Daily Target 2X Short RKLB ETF, meaning it is designed to deliver twice the inverse daily return of Rocket Lab stock. With no news about RKLZ itself appearing in the headlines, the most plausible explanation is that the underlying Rocket Lab (RKLB) stock fell significantly during the period, causing this short ETF to gain substantially. Leveraged and inverse ETFs amplify daily moves, so even a modest decline in RKLB would be magnified roughly twofold in RKLZ. Without access to RKLB's price action or news on Rocket Lab specifically, we cannot confirm the exact trigger, but a major sell-off in the aerospace or space sector, negative guidance, operational setback, or broad market weakness affecting growth stocks are plausible categories. The absence of RKLZ-specific news makes a structural explanation the most likely driver here.

OPTU

Optimum Communications, Inc.Communication Services

$1.61+$0.26

+19.3%

NAIL

Direxion Daily Homebuilders & Supplies Bull 3X ETF

$51.20+$8.09

+18.8%

AMEX

No news headlines were found in the last 48 hours, but NAIL is a 3X leveraged bull ETF on homebuilders, so an 18.77% jump likely reflects a strong rally in the underlying homebuilding sector, possibly driven by housing data, Fed policy signals, or mortgage rate movements.

The absence of news directly tied to NAIL itself is notable. However, this security is a leveraged derivative product that amplifies daily moves in the homebuilding and supplies sector by 3X. An 18.77% move in a 3X bull ETF implies approximately a 6% move in the underlying index on a day when housing or building-related equities rallied. This could stem from several categories of catalysts: positive housing starts or building permits data, mortgage rate declines, positive consumer confidence signals, or favorable Federal Reserve commentary on rate policy. Without specific headlines in the provided feed, the exact trigger cannot be pinpointed, but sector-level macro data releases or Fed communications are the most common drivers of homebuilder volatility. The leverage mechanism itself explains why this ETF ranks in the top 25 gainers despite being a basket fund.

SSM

Sono Group N.V.Consumer Cyclical

$4.58+$0.72

+18.7%

NASDAQ · Mkt cap $3.8 M

No news headlines were found in the last 48 hours, so the 18.65% gain likely reflects technical trading activity, a delayed market reaction to an earlier announcement, or sentiment shift in a volatile small-cap stock like Sono Group.

Sono Group is a solar-panel electric vehicle startup that trades on NASDAQ with relatively modest liquidity and market capitalization, making it susceptible to large single-day swings on thin volume or sentiment shifts. The absence of fresh news in the 48-hour window suggests the move was not triggered by a new corporate announcement, earnings release, or major business development. For micro-cap or distressed growth stocks in this space, gains of this magnitude often stem from short covering, retail momentum trading, a delayed positive reaction to an earlier press release outside the RSS feed window, technical support bouncing, or broader sector rotation into clean energy. Without concrete evidence of a specific catalyst, attribution must remain speculative. The ranking as the 24th biggest gainer suggests this move occurred alongside normal market activity, not in isolation.

LIFE

Ethos Technologies Inc.Financial Services

$18.10+$2.84

+18.6%

NASDAQ · Mkt cap $3.6 B

No news headlines were found in the last 48 hours for LIFE, so the 18.61% gain cannot be directly attributed to a specific announced event. The move may reflect technical trading, delayed news coverage, or market sentiment shift.

The absence of recent headlines in the provided news feed means we cannot point to a specific catalyst such as earnings, regulatory approval, partnership, or guidance change. This is a notable constraint since an 18.61% single-day jump for a mid-cap stock typically warrants public disclosure or at least coverage within 48 hours. Possible inference categories include: a technical or short-squeeze driven rally unrelated to fundamental news; a delayed market reaction to news not yet captured in this feed; or sector-wide momentum affecting biotech or healthcare stocks. Without access to broader market data, company filings, or earlier news archives, we cannot distinguish between these scenarios. The rank as the 25th biggest gainer suggests real volume and interest, but the lack of news makes the specific reason opaque.

SMST

Defiance Daily Target 2x Short MSTR ETF

$74.32+$11.62

+18.5%

NASDAQ

No news headlines were found in the last 48 hours, but SMST is a 2x leveraged short ETF on MSTR (MicroStrategy), so a sharp gain likely reflects a significant drop in the underlying stock price.

The absence of news headlines makes direct causation impossible to establish from the provided information. However, SMST's structure is critical context: it is a daily target 2x inverse leveraged fund, meaning it is designed to move roughly twice as much as MicroStrategy stock does, but in the opposite direction. A +18.53% gain in SMST would be consistent with a roughly 9-10% decline in MSTR on this date. This suggests the move is not driven by news about SMST itself but rather by a significant adverse price movement in MicroStrategy, the underlying asset the ETF shorts. The catalyst for MSTR's decline could be broad market conditions, company-specific developments, or technical selling, but without access to MicroStrategy news or price data, the root cause cannot be confirmed.

BNC

CEA Industries Inc. Common StockIndustrials

$2.69+$0.42

+18.5%

NASDAQ · Mkt cap $108 M

No news headlines were found in the last 48 hours, so the 18.5% gain likely reflects either a delayed market reaction to earlier events, technical buying, or untracked company developments.

BNC rose 18.5% to rank among the day's top 25 gainers despite zero news coverage in the Yahoo Finance RSS feed over the preceding two days. This disconnect suggests either a delayed reaction to news older than 48 hours, an untracked internal event such as a private press release or regulatory filing not yet indexed by major aggregators, or a technical catalyst such as short covering or options-related buying. Without access to real-time Twitter activity, SEC filings, or company investor relations channels, the specific driver cannot be determined from the evidence available. The stock's relatively modest price of $2.69 may make it susceptible to retail or algorithmic trading momentum, which could also explain a gap between company-level catalysts and headline coverage.

NDRA

ENDRA Life Sciences Inc.Healthcare

$6.27+$0.96

+18.1%

NASDAQ · Mkt cap $5.7 M

ENDRA Life Sciences surged 18.08% on June 24, 2026, but no news headlines were published in the prior 48 hours to explain the move, suggesting the catalyst may be an intraday rumor, technical event, or delayed disclosure.

No headlines are available in the Yahoo Finance RSS feed for the last 48 hours surrounding this +18% gain. This absence makes it difficult to identify a specific catalyst. ENDRA is a small-cap medical device or life sciences company, and stocks in this category often respond sharply to clinical trial results, FDA approvals or communications, partnership announcements, or guidance updates. The gain's magnitude and ranking as the 28th biggest gainer suggests it is material news rather than pure technical momentum, but without headline evidence we cannot confirm whether the driver was an official press release, an analyst upgrade, insider activity, short covering, or market gossip. The lack of documented news in a major feed within 48 hours of a 18% move is noteworthy and limits confident attribution.

QNRX

Quoin Pharmaceuticals, Ltd.Healthcare

$3.83+$0.58

+17.8%

NASDAQ · Mkt cap $10 M

Quoin Pharmaceuticals received FDA conditional approval of the brand name QYLEKI for its QRX003 drug candidate for Netherton Syndrome on June 23, a regulatory milestone that likely drove the 17.85% jump as it signals progress toward commercialization of an orphan drug with multiple designations.

The headline from June 23 establishes that the FDA conditionally approved QYLEKI as the proposed brand name for QRX003, Quoin's treatment for Netherton Syndrome. This is a concrete regulatory event for a rare pediatric disease where the drug already holds orphan drug designation in the US, EU, and Japan, plus Fast Track and Rare Pediatric Disease designations from the FDA. Brand name approval is a procedural step that typically precedes final approval and market launch, signaling regulatory momentum. For a small-cap orphan drug developer, such milestones are material catalysts because they reduce execution risk and bring commercialization closer. The timing of the news on June 23 matches the stock's gain on June 24, establishing a direct causal link. The announcement also notes that a pivotal Phase 3 study is expected to initiate in the second half of 2026, providing near-term catalysts.

QTRX

Quanterix CorporationHealthcare

$3.78+$0.56

+17.4%

NASDAQ · Mkt cap $140 M

A Yahoo Finance headline confirms QTRX surged after-hours on Tuesday alongside other small-cap stocks, but provides no specific catalyst for the 17.4% gain; the actual news driver remains undisclosed.

The headline explicitly states that QTRX surged between 6% and 27% after-hours on Tuesday alongside stocks TRIB and RCON, but does not name or describe the underlying reason for the move. The article appears to be a roundup of gainers rather than a news-driven report tied to earnings, FDA approval, partnerships, clinical data, or guidance. For a biotech company like Quanterix—which develops ultrasensitive protein detection platforms—typical catalysts include clinical trial results, reimbursement decisions, partnership announcements, or revenue guidance. The headline's focus on "why" these stocks are surging suggests a specific event occurred, but the provided text does not reveal it. Without access to the full article or additional news sources, the catalyst remains inference rather than fact.

AARD

Aardvark Therapeutics, Inc. Common StockHealthcare

$4.96+$0.73

+17.3%

NASDAQ · Mkt cap $148 M

No news headlines were found in the last 48 hours, so the 17.26% gain cannot be attributed to a specific announced catalyst. The jump likely reflects technical trading, sector momentum, or information not captured in this feed.

Aardvark Therapeutics stock rose 17.26% on June 24, 2026, ranking it among the day's top 31 gainers, yet no news headlines from the prior 48 hours are available to explain the move. This disconnect suggests the catalyst either originated outside the monitored news feed, occurred earlier and is now being repriced, or reflects intraday technical factors. For a small-cap biotech name like this, typical drivers of single-day spikes include clinical trial results, FDA correspondence, partnership announcements, or insider buying. Without access to press releases, regulatory filings, or institutional news sources beyond Yahoo Finance's RSS, we cannot determine which category applies. The absence of negative headlines at least rules out sudden bad news, but that does not identify what drove the gain.

CCXIU

Churchill Capital Corp XI UnitsFinancial Services

$12.50+$1.83

+17.2%

NASDAQ

Churchill Capital Corp XI (CCXIU) surged 17.15% following the announcement of a definitive merger agreement with Agility Robotics, a humanoid robotics company valued at $2.5 billion, which will become the first pure-play humanoid robot company trading on the Nasdaq.

The headlines establish a clear catalyst: Churchill Capital Corp XI announced on June 24, 2026, a definitive merger with Agility Robotics, Inc., a leading humanoid robotics and physical AI developer. The deal values Agility at $2.5 billion and is expected to provide over $620 million in proceeds to the combined entity. Multiple news sources confirm the announcement broke on June 24, with the combined company set to trade under the ticker AGLT. The 17.15% gain aligns with intraday price action reported in the headlines, where shares initially climbed 14% and even briefly jumped nearly 30% at open, before settling at this gain level by close. SPAC mergers with high-growth technology companies, particularly those in emerging sectors like humanoid robotics, typically attract investor interest given the sector's growth narrative and Nvidia backing mentioned in one headline.

SNTI

Senti Biosciences, Inc.Healthcare

$1.08+$0.16

+16.8%

NASDAQ · Mkt cap $14 M

No news headlines were found in the last 48 hours for Senti Biosciences, so the 16.82% gain on June 24 cannot be attributed to a specific disclosed event; the move likely reflects technical factors, rumors, or delayed market reaction to an announcement not yet captured in the news feed.

Despite a substantial single-day gain placing SNTI in the top 33 gainers, no recent news headlines are available to explain the move. Senti Biosciences is a clinical-stage cell therapy company, which makes it sensitive to clinical trial updates, regulatory decisions, partnership announcements, or financing news. The absence of headlines in the 48-hour window suggests either that the catalyst occurred earlier and is experiencing delayed price discovery, that the move was driven by technical factors such as short covering or algorithmic trading, or that relevant news has not yet been indexed by the financial wire services included in this feed. Small-cap biotech stocks often exhibit volatile price action disconnected from same-day news flow.

KBH

KB HomeConsumer Cyclical

$61.51+$8.78

+16.7%

DFTX

Mind Medicine (MindMed) Inc.Healthcare

$42.13+$5.95

+16.4%

NASDAQ · Mkt cap $5.1 B

Definium Therapeutics announced positive Phase 3 trial results for its LSD-based depression treatment DT120 on June 22-23, showing rapid and durable efficacy with a favorable safety profile, and simultaneously announced a $700 million public offering, driving the stock up 16.45% on June 24.

The headlines establish that Definium reported its Phase 3 Emerge trial met primary and all key secondary endpoints for DT120 ODT in major depressive disorder, described as "best-case" results showing a single 100-microgram dose delivered significant antidepressant effects superior to placebo. The company concurrently announced a $700 million upsized public offering priced on June 24. Multiple sources confirm the trial win occurred June 22-23, with the company capitalizing on momentum to price the offering. One analyst note highlights that the win validates the broader psychedelics field, suggesting market enthusiasm extends beyond DFTX to its competitors. The 16.45% move on June 24 likely reflects both the confirmation of trial success through mainstream media coverage and the pricing of the capital raise, which signals management confidence and provides runway for the company to advance toward potential regulatory approval.

RGTZ

Daily Target 2X Short RGTZ ETF

$3.77+$0.53

+16.4%

NASDAQ

No news headlines appeared in the last 48 hours, but RGTZ is a 2X short leveraged ETF, so a 16% gain likely reflects a sharp decline in its underlying asset (RGTZ stock) that was amplified by the fund's inverse leverage structure.

RGTZ is a daily target 2X short ETF, meaning it is designed to move in the opposite direction of its underlying benchmark with 2X daily leverage. With no news headlines available from the past 48 hours, the 16% surge cannot be attributed to company-specific or sector news. However, the price action is structurally explainable: if the underlying reference equity fell sharply on a given day, the 2X short fund would gain approximately twice that decline percentage. A roughly 8% drop in the underlying would generate a 16% gain in RGTZ under ideal daily reset conditions. This move is consistent with a broad market pullback or a collapse in a specific stock that RGTZ tracks short. Without news, the catalyst could be technical selling, macro headwinds, or delayed market reaction to earlier announcements.

QBTZ

Defiance Daily Target 2X Short QBTS ETF

$4.29+$0.60

+16.3%

NASDAQ

No news headlines were found in the last 48 hours. QBTZ is a 2X inverse leveraged ETF, so a 16% gain likely reflects a sharp decline in its underlying index QBTS, amplified by the 2X short mechanism.

The absence of recent news headlines makes it impossible to pinpoint a specific catalyst. However, QBTZ is structured as a daily target 2X short leveraged ETF, meaning it moves in the opposite direction of its underlying benchmark at approximately double the amplitude. A 16% single-day gain in QBTZ would correspond to roughly an 8% decline in the underlying QBTS index. This type of move in a leveraged inverse product typically occurs during broad market selloffs, sector rotation, or sharp declines in whatever benchmark QBTS tracks. Without access to QBTS's own price action or relevant market news, the exact trigger cannot be identified, but the gain is consistent with a significant down move in the underlying security.

AQB

AquaBounty Technologies, Inc.Consumer Defensive

$1.18+$0.17

+16.3%

NASDAQ · Mkt cap $6.8 M

AquaBounty Technologies surged 16.26% on June 24, 2026, but no news headlines were available in the prior 48 hours to identify a specific catalyst for the move.

The absence of recent news headlines makes it difficult to pinpoint the exact cause of AQB's 16.26% gain. However, aquaculture and biotech stocks in this category often respond to regulatory approvals, product commercialization milestones, partnership announcements, or clinical or operational updates that may not always appear immediately in major news feeds. The stock's relatively low price of $1.18 suggests it trades in penny or micro-cap territory, which can amplify percentage moves on modest volume shifts or delayed media coverage of company announcements. Without documented headlines, the move could reflect a delayed market reaction to an earlier press release, technical momentum, or a development not yet captured by Yahoo Finance's RSS feed.

NVNO

enVVeno Medical CorporationHealthcare

$11.37+$1.58

+16.1%

NASDAQ · Mkt cap $8.1 M

No news headlines are available in the last 48 hours for NVNO, so the 16.14% gain cannot be directly attributed to a specific catalyst based on provided information. The move likely reflects either delayed market reaction to an earlier announcement, technical trading activity, or a company develo…

The absence of recent headline coverage makes it difficult to pinpoint the exact driver of today's 16.14% jump in NVNO. For a smaller medical device company like enVVeno Medical, typical catalysts include clinical trial results, regulatory approvals or FDA feedback, partnership announcements, or institutional investment decisions. The stock could be responding to an earnings report or investor presentation released yesterday that hasn't yet propagated through the RSS feed, or to a development from earlier in the week that is only now gaining market traction. Alternatively, the move could reflect short covering, options-driven positioning ahead of an upcoming event, or a general rotation toward a sector or subsector. Without corroborating news, all of these remain speculative.

AALG

Leverage Shares 2x Long AAL Daily ETF

$19.16+$2.62

+15.8%

NASDAQ

No news headlines were found in the last 48 hours, but AALG is a 2x leveraged ETF tracking American Airlines, so the +15.82% gain likely reflects a significant rise in AAL stock itself, amplified by the fund's 2x daily leverage structure.

The absence of breaking news in the past 48 hours does not explain the move directly. However, AALG is a structured product designed to deliver twice the daily return of American Airlines (AAL) stock. A +15.82% move in the ETF would correspond roughly to an approximately +7.9% move in AAL itself, which is material but not extreme for an airline stock during a single session. Airline stocks are sensitive to fuel prices, macroeconomic sentiment, travel demand signals, and broader equity market rallies. Without specific headlines provided, the most probable causes are either positive airline sector momentum, a favorable market-wide rally that lifted cyclical stocks, or positive developments in AAL that have not yet appeared in the Yahoo Finance RSS feed used for this analysis.

IRHOR

Iron Horse Acquisitions Corp. II Rights

$0.21+$0.03

+15.6%

NASDAQ

No news headlines were found in the last 48 hours explaining the 15.64% gain in IRHOR, a SPAC rights offering, so the move likely reflects either technical trading activity, delayed market reaction to prior events, or speculative positioning in a low-float security.

Iron Horse Acquisitions Corp. II Rights is a special purpose acquisition company rights offering, a security category known for low trading volume and high volatility. The absence of recent news headlines does not preclude a price move, particularly in illiquid SPAC-related instruments. Rights offerings can experience sharp moves based on several structural factors: changes in sentiment toward the underlying SPAC's merger timeline or target, adjustments in implied warrant or equity valuations, or simply thin-market technical moves where modest volume can shift prices meaningfully. Additionally, such securities occasionally react to broader SPAC market sentiment or news about the sponsor's other deals. Without specific headline evidence, the most probable causes are technical rebalancing, options-related hedging flows, or retail interest in low-priced securities.

BDTX

Black Diamond Therapeutics, Inc.Healthcare

$1.86+$0.25

+15.5%

NASDAQ · Mkt cap $116 M

No news headlines were found in the last 48 hours, so the 15.53% gain likely reflects either a delayed market reaction to an earlier announcement, technical trading, or a company-specific catalyst not yet captured in available news feeds.

Black Diamond Therapeutics is a precision oncology company focused on developing therapies for difficult-to-treat cancers. The stock gained over 15% with no recent news headlines available, which suggests either a lag in news indexing by Yahoo Finance, a reaction to pre-market information or rumors, or momentum-driven technical trading in a stock that may trade with higher volatility. For a biotech company like BDTX, typical catalysts would include clinical trial results, regulatory interactions with the FDA, partnership announcements, or financing developments. Without specific headlines, it is impossible to confirm which of these occurred. The absence of news combined with the notable gain suggests the move may be partially speculative or based on information not yet widely distributed through major news feeds.

WYY

WidePoint CorporationTechnology

$17.62+$2.35

+15.4%

AMEX · Mkt cap $91 M

WidePoint was named a prime contract awardee on NASA's $60 billion SEWP VI contract, announced on June 23, which likely drove the 15.39% stock surge the following day as investors reacted to the significant government contract award.

The headline establishes that WidePoint Corporation received a prime contract awardee designation on NASA's $60 billion SEWP VI (Solutions for Enterprise-Wide Procurement) contract. This is a material corporate development event for a company focused on secure mobile management solutions, as it represents validation from a major federal customer and access to a substantial contracting vehicle. Government contract awards of this scale typically generate investor enthusiasm due to the implied revenue opportunity, customer creditworthiness, and competitive positioning they signal. The timing of the announcement on June 23 at 16:40 UTC followed by the stock's +15.39% move ranking it 43 among daily gainers suggests the market reaction was direct and positive. Without additional context on contract value allocated to WidePoint specifically or financial guidance updates, we cannot quantify the revenue impact, but the designation itself appears sufficient to explain the sharp upward move.

UCAR

U Power LimitedConsumer Cyclical

$1.28+$0.17

+15.3%

NASDAQ · Mkt cap $15 M

No news headlines were found in the last 48 hours for UCAR, so the 15.32% gain likely reflects technical trading, delayed news dissemination, or market rumors rather than a confirmed corporate event.

The absence of recent Yahoo Finance headlines makes it impossible to identify a specific catalyst for today's 15.32% jump in UCAR stock price. For a lower-priced stock like UCAR trading at $1.28, price moves of this magnitude can be driven by several categories of factors: delayed or non-indexed news coverage of earnings, guidance changes, or strategic announcements; technical factors such as short covering or algorithmic trading activity; or market rumors and social media momentum that precede formal press releases. Without access to earnings calendars, regulatory filings, or company announcements outside the RSS feed provided, we cannot distinguish among these possibilities. The fact that UCAR ranked as the 44th biggest gainer suggests meaningful volume participation, but volume alone does not reveal intent or source.

JACK

Jack in the Box Inc.Consumer Cyclical

$13.35+$1.77

+15.3%

NASDAQ · Mkt cap $321 M

Jack in the Box rose 15.29% following announcement of a $500 million securitized financing facility completed on June 23, which likely signals improved financial flexibility and de-risking of the balance sheet.

The company announced completion of a $500 million securitized financing facility through a subsidiary on June 23, the day before the stock surge. This type of transaction typically indicates strengthened liquidity, improved access to capital markets, and potential refinancing of existing debt at favorable terms. The securitization allows the company to monetize future cash flows, which is generally viewed positively by equity investors as it reduces near-term refinancing risk and may lower the cost of capital. The earlier headline about rising farm costs pressuring QSR stocks (June 23 early) was offset by the financing announcement later that day, suggesting the market weighted the capital structure improvement more heavily. No earnings beat, product launch, or operational catalyst is evident in the headlines, making the financing announcement the most concrete and recent catalyst for the 15% gain.

TDWDR

Tailwind 2.0 Acquisition Corp. Rights

$0.14+$0.02

+15.2%

NASDAQ

No news headlines were found in the last 48 hours, so the 15.23% gain in TDWDR rights shares likely reflects either technical trading activity in a low-liquidity security or market reaction to developments in the underlying SPAC merger process not yet captured in headlines.

Tailwind 2.0 Acquisition Corp. Rights (TDWDR) is a SPAC rights offering, a security type with characteristically low liquidity and high volatility even on modest dollar volume. The absence of recent news headlines does not rule out a catalyst; it may indicate that relevant information (such as merger vote announcements, deal timeline updates, or shareholder communications) was distributed through SEC filings, company press releases, or investor relations channels not covered by the Yahoo Finance RSS feed used here. Alternatively, the move could reflect short-covering in a thin-traded security, rotation of retail capital into SPAC arbitrage positions, or technical momentum. Without specific news or SEC filings accessible in this snapshot, the exact cause remains unclear, though SPAC rights are particularly prone to sharp moves on modest volume shifts.

CCXI

Churchill Capital Corp XIFinancial Services

$11.99+$1.57

+15.1%

ZSL

ProShares - UltraShort Silver

$32.97+$4.17

+14.5%

FOUR

Shift4 Payments, Inc.Technology

$44.22+$5.55

+14.4%

NYSE · Mkt cap $3.3 B

Shift4 Payments shares surged 14.35% on news of a proactive debt management plan and analyst confidence ahead of upcoming quarterly results, reflecting reduced financial risk and positive momentum into earnings.

The headline indicates that Shift4 announced a debt management plan designed to strengthen its balance sheet, which appears to have been well-received by the market. An analyst also expressed confidence in the company's forthcoming quarterly earnings, suggesting positive expectations for near-term results. For a payment processor, debt reduction signals improved financial flexibility and lower refinancing risk, while analyst optimism ahead of earnings typically attracts buying pressure. The 14.35% gain is substantial but not unusual for a mid-cap fintech stock responding to both balance sheet news and forward guidance signals. The headline itself is truncated mid-sentence, so some detail about the analyst commentary and specific debt plan parameters is not fully visible, but the core drivers of the move are clearly identified in the news summary.

COOK

Traeger, Inc.Consumer Cyclical

$78.49+$9.74

+14.2%

NYSE · Mkt cap $164 M

No news headlines were found in the last 48 hours to explain Traeger's 14.17% jump on June 24, 2026. The move likely reflects a delayed market reaction to a prior announcement, technical reversal, or untracked fundamental catalyst.

The absence of any Yahoo Finance headlines in the most recent 48-hour window means we cannot identify a specific news catalyst for this substantial gain. Traeger is a consumer discretionary stock in the outdoor cooking space, which can be sensitive to quarterly earnings reports, guidance revisions, management changes, or operational announcements that drive investor sentiment. It is also possible this move represents a technical bounce after prior weakness, short covering, or reaction to sector-wide strength in consumer or retail stocks. Without headline evidence, we cannot distinguish between these possibilities. The stock's rank as the 50th biggest gainer suggests material interest but does not clarify the underlying cause.

Biggest Losers

Wed, Jun 24, 2026 50

ATLN

Atlantic International Corp.Industrials

$0.78−$0.55

-41.3%

NASDAQ · Mkt cap $61 M

ATLN surged 150% on June 23 after announcing a $52 million government contract, but then collapsed 41% the next day, suggesting either profit-taking, a negative follow-up disclosure, or market skepticism about deal sustainability.

The stock experienced extreme volatility around the same contract announcement. The June 23 headlines confirm a concrete $52 million government contract award to Seven Stars B.V., a Circle8 Group subsidiary, which drove a 150% rally on that date. However, the 41% drop on June 24 within 24 hours of that positive news is unusual and suggests several possibilities. The most likely explanations are aggressive short-covering reversing after the initial spike, retail profit-taking on a triple-digit gain, or the market discovering material details in fine print (contract timing, revenue recognition delays, execution risk) that were not prominent in the initial headlines. A secondary possibility is that a negative follow-up news item emerged but was not captured in the provided RSS feed. Without additional reporting from June 24, we cannot definitively attribute the reversal to fundamentals versus pure sentiment and technical reversal.

HTZ

Hertz Global Holdings, Inc.Industrials

$3.00−$2.06

-40.7%

NASDAQ · Mkt cap $809 M

Hertz issued a second-quarter earnings warning citing weaker-than-expected demand for used-car rentals and announced a $400 million capital raise via stock and debt offerings, triggering a 40.7% single-day sell-off.

The headlines establish a clear cause: on June 24, Hertz cut its Q2 earnings guidance, citing unexpected softness in the used-car rental market. Simultaneously, the company announced plans to raise $100 million through a common stock offering and $300 million through exchangeable senior secured notes. Both actions signal financial stress and shareholder dilution. The stock fell over 20% in pre-market trading and continued declining through the session to close down 40.71%, making it the second-biggest loser of the day. This magnitude of decline reflects a confluence of negative signals: diminished near-term profitability, balance-sheet concern severe enough to warrant immediate capital raises, and dilution of existing shareholder equity. The used-car market weakness is a business-specific headwind; the capital raise is a structural concern that typically weighs heavily on equity valuations.

TOYO

TOYO Co., Ltd.Technology

$7.91−$5.02

-38.8%

NASDAQ · Mkt cap $185 M

TOYO announced a $50 million registered direct offering on the day of the crash, which typically dilutes existing shareholders and triggered the 38.82% sell-off as investors reacted to immediate share dilution.

A registered direct offering (RDO) is a capital raise in which a company sells shares directly to investors at a negotiated price, typically below the current market price. The announcement itself signals dilution of existing shareholders' ownership stakes and often reflects capital needs or operational pressures. While the full terms of TOYO's offering—including the discount to market price and number of shares issued—are not detailed in the headline provided, the timing and magnitude of the decline strongly suggest investors reacted negatively to the dilution news. For a solar manufacturing company, such capital raises can indicate pressure to fund operations, invest in capacity, or address debt. The 38.82% single-day drop is severe but not uncommon for RDO announcements in smaller-cap stocks, particularly if the discount or share count was perceived as unfavorable.

CGTX

Cognition Therapeutics, Inc.Healthcare

$1.02−$0.63

-38.2%

NASDAQ · Mkt cap $93 M

Cognition Therapeutics stock crashed 38% despite receiving positive FDA feedback on its Phase 3 trial design for zervimesine in DLB psychosis, suggesting the market either expected more favorable terms or interpreted the feedback as insufficient catalyst relative to the stock's current valuation …

The company announced that the FDA aligned with key aspects of its pivotal Phase 3 study plan for CT1812 (zervimesine), positioning it as a potential first long-term treatment for DLB psychosis with Phase 3 expected to begin mid-2027. An early report noted the stock gained 5% on this announcement, but by afternoon the stock had reversed sharply into a 33-38% decline despite the positive regulatory feedback persisting. This inversion is unusual and suggests the market may have reassessed either the significance of the FDA alignment relative to the long development timeline ahead, concerns about competitive dynamics not mentioned in the headlines, doubts about the commercial opportunity for this indication, or risk of stock dilution not disclosed in these excerpts. The positive FDA feedback alone does not typically trigger such sharp reversals for clinical-stage biotech unless paired with disappointing guidance, financing news, or competitive threat.

JLHL

Julong Holding Limited Class A Ordinary SharesIndustrials

$13.25−$6.25

-32.1%

NASDAQ · Mkt cap $152 M

No financial news appeared in the last 48 hours, so the 32% drop cannot be attributed to a disclosed catalyst. The decline may reflect a delayed market reaction to an earlier announcement, technical selling, or undisclosed company-specific developments.

The absence of any Yahoo Finance headlines in the past 48 hours makes it impossible to pinpoint a specific news-driven cause for JLHL's severe 32% decline. A drop of this magnitude typically requires a material catalyst such as earnings disappointment, dividend suspension, guidance cut, regulatory action, or significant corporate event. Since no such headline is documented here, three inference categories are plausible: first, the news may have broken before the 48-hour window; second, negative sentiment could stem from sector-wide or macro headwinds affecting small-cap or China-listed companies; or third, an announcement may have been made through channels other than Yahoo Finance's RSS feed and has not yet been widely indexed. Without a documented trigger, the exact cause remains speculative.

NUWE

Nuwellis, Inc.Healthcare

$0.09−$0.04

-30.5%

NASDAQ · Mkt cap $3.7 M

Nuwellis stock plunged 30.47% despite an incoming CEO letter outlining strategic priorities; the timing suggests market disappointment with either the content of the plan or broader weakness in the micro-cap medical device sector.

The headline released today features incoming CEO Mike McCormick's shareholder letter emphasizing strategic priorities in pediatric expansion and revenue generation. However, the headline provided contains no specific financial targets, contract announcements, FDA approvals, or quantified milestones that would normally justify a 30% rally. The stark mismatch between a forward-looking strategic communication and a severe single-day decline suggests either that the full letter contained disappointing details not captured in the headline excerpt, or that market participants interpreted the messaging as insufficient to address underlying concerns about the company's trajectory. Nuwellis is a small-cap medical device company with historically volatile trading; such moves can also reflect technical selling, sector rotation, or negative commentary from analysts that wasn't included in the provided news snapshot.

FRTT

Fort Technology Inc. Common SharesConsumer Cyclical

$1.27−$0.50

-28.2%

NASDAQ · Mkt cap $11 M

Fort Technology announced a strategic partnership and investment proposal with Logia USA for data center power infrastructure, but the market's sharp 28% sell-off suggests investor skepticism about execution, valuation, or deal terms rather than enthusiasm for the initiative.

The June 24 headline describes a letter of intent for a proposed partnership and investment aimed at providing power infrastructure solutions to the estimated $300 billion data center market. While the announcement frames this as positive strategic positioning, the stock's severe decline indicates the market did not view it favorably. Possible explanations include concern about dilution from the investment structure, doubt about Fort Technology's ability to execute in a highly competitive sector, unclear financial terms or commitment levels in a mere letter of intent stage, or broader sector weakness in small-cap tech. The use of cautious language like "aims to evaluate feasibility" rather than a definitive deal may have also signaled weakness. Without details on valuation, investment size, or deal certainty, investors may have punished the stock for perceived execution risk or unfavorable terms.

SDOT

Sadot Group Inc.Consumer Defensive

$7.25−$2.85

-28.2%

NASDAQ · Mkt cap $11 M

SDOT dropped 28.18% with no recent news headlines available, making the precise catalyst unclear; the decline likely reflects either a delayed market reaction to an earlier announcement, technical selling, or undisclosed company-specific event.

No news headlines appeared in the last 48 hours according to the data provided, yet SDOT suffered a severe single-day loss ranking it among the eight biggest losers on NASDAQ. This disconnect between magnitude of move and absence of public headlines suggests several possibilities. First, a significant announcement or guidance change may have occurred but not yet been indexed in the Yahoo Finance RSS feed at the time of this snapshot. Second, the stock could be reacting to broader sector weakness or market conditions that affected multiple small-cap stocks simultaneously. Third, given the severity of the decline and lack of accompanying news, technical factors such as stop-loss cascades, options expiration effects, or heavy short positioning could have contributed to the sharp selloff. Without access to intraday trading data or company filings from the snapshot date, determining the specific catalyst remains speculative.

BGL

Blue Gold LimitedBasic Materials

$0.28−$0.11

-27.9%

NASDAQ · Mkt cap $7.9 M

BGL dropped 27.94% with no news headlines in the last 48 hours, suggesting the move was driven by technical selling, market sentiment, or undisclosed corporate developments not yet reflected in public reporting.

The absence of any recent news headlines makes it impossible to identify a specific catalyst for the sharp 27.94% decline. Blue Gold Limited's stock rank as the ninth biggest loser suggests sector-wide weakness or a company-specific event that either occurred before the 48-hour window or has not yet been publicly announced or indexed by news aggregators. For a micro-cap security trading at $0.28, typical drivers of sudden sharp declines include liquidity crises, insider selling, failed clinical or exploration results (if biotech or mining), covenant breaches, dilutive financing announcements, or loss of a major customer or contract. Without access to earnings reports, SEC filings, press releases, or analyst downgrades from the relevant period, the actual cause cannot be determined from the data provided.

VMAR

Vision Marine Technologies Inc.Consumer Cyclical

$1.96−$0.76

-27.9%

NASDAQ · Mkt cap $4.6 M

Vision Marine announced a positive USPTO patent allowance on June 24, but the stock plummeted 27.94% the same day, suggesting the market either viewed the patent as immaterial, reacted to a concurrent negative catalyst not disclosed in available headlines, or sold on the news after prior anticipa…

The only headline provided is a USPTO Notice of Allowance for the company's electric-vessel powertrain authentication patent, which is typically a positive development for intellectual property positioning. However, a 27.94% single-day drop contradicts the notion that this patent approval drove the loss. Three explanations fit the data: first, the patent was already priced in and the market used the announcement as an opportunity to exit; second, a material negative catalyst—such as dilutive financing, executive departure, clinical setback, or failed business partnership—occurred simultaneously but is absent from the Yahoo Finance RSS feed provided; third, broader market stress in marine technology or small-cap equities triggered sector-wide selling pressure. Without additional news, the patent allowance appears insufficient to explain the magnitude of the decline, suggesting either missing information or a technical/sentiment reversal unrelated to the disclosed patent event.

GPUS

Hyperscale Data, Inc.Industrials

$0.19−$0.07

-27.0%

AMEX · Mkt cap $31 M

Hyperscale Data announced multiple major wins today including a $1.2B-$3B AI compute deal and 125 MW of new power capacity at its Montana site, yet the stock fell 27%, suggesting the market may be pricing in execution risk, valuation concerns, or dilution from financing needs required to build ou…

The headlines are counterintuitive at first glance. Hyperscale Data announced three materially positive developments on June 24: a master services agreement worth up to $3 billion for AI compute, an initial $1.2 billion contract with a California neocloud provider for 20 MW, and utility approval for 125 additional megawatts of power at its Montana facility. These would typically be rally catalysts. However, the 27% decline suggests the market is skeptical about execution, capital requirements, or valuation at current levels. The shift from Bitcoin mining to AI compute, while strategic, requires substantial capex that may require dilutive financing. Alternatively, the stock may have already priced in expectations of these deals, or the market is discounting near-term profitability given the build-out timeline required to monetize committed capacity.

CALC

CalciMedica, Inc.Healthcare

$0.60−$0.21

-25.6%

NASDAQ · Mkt cap $19 M

CalciMedica announced positive FDA news permitting continued development of Auxora and a $49 million financing, yet the stock fell 25.64%, suggesting market disappointment with either the financing terms, dilution concerns, or unmet expectations about trial results or trial scope.

CalciMedica released two pieces of news on the same day: clearance to proceed with clinical development following FDA review of interim safety data from the KOURAGE trial, and a private placement financing of approximately $49 million to advance a pulmonary hypertension program. On the surface, both announcements are constructive—the FDA allowed continuation rather than halting the program, and new capital supports pipeline advancement. However, the 25.64% decline suggests the market viewed the outcomes negatively. Possible explanations include disappointment that the FDA did not greenlight an accelerated pathway, concern that the financing terms were dilutive to existing shareholders (typical for clinical-stage biotech), interpretation that interim safety data, while permitting continuation, failed to show efficacy signals or were weaker than hoped, or that the trial scope or timeline disappointed investors relative to prior expectations. Without detail on trial efficacy readouts or financing terms, we cannot pinpoint which factor drove the sell-off.

APURR

Aperture AC

$0.16−$0.05

-23.8%

NASDAQ

No news headlines were found in the last 48 hours, so the 23.81% drop likely stems from technical selling, a delayed announcement, or sector-wide pressure rather than a specific company event.

The absence of recent news headlines makes it difficult to pinpoint a definitive cause for the sharp decline. APURR is a micro-cap stock trading at $0.16, and stocks at this price level are typically more vulnerable to technical breakdowns, retail selling pressure, and low-volume cascades that can amplify intraday moves. Possible explanations include sector rotation out of small-cap equities, a negative development disclosed after market close on June 23, an earnings miss or guidance cut that hit wires late, or simply thin liquidity exaggerating a modest sell signal. Without access to company announcements, SEC filings, or earnings reports from the critical window, any explanation remains speculative. The lack of headline coverage itself may suggest the move was driven by internal trading patterns rather than external news.

BNRG

Brenmiller Energy LtdUtilities

$0.83−$0.26

-23.6%

BJDX

Bluejay Diagnostics, Inc.Healthcare

$2.99−$0.89

-22.9%

NASDAQ · Mkt cap $1.0 M

No news headlines were found in the last 48 hours, so the 22.94% single-day drop cannot be directly attributed to a reported event; the decline likely reflects market sentiment, technical selling, or unreported developments.

The absence of any news in the Yahoo Finance RSS feed over the past 48 hours is notable given the magnitude of BJDX's decline, which ranked it among the top 15 biggest losers on June 24, 2026. For a diagnostics company trading at $2.99, such moves are typically triggered by clinical trial results, regulatory setbacks, financing announcements, or guidance revisions. The lack of headlines suggests either that the catalyst was not yet widely reported through major news feeds at the time of this snapshot, that the decline was driven by intraday technical factors or sector-wide weakness, or that a material announcement may have occurred through channels not captured by standard RSS feeds. Without visibility into earnings reports, trial data, or company guidance issued on or immediately before June 24, any specific cause remains speculative.

RGC

Regencell Bioscience Holdings LimitedHealthcare

$8.56−$2.52

-22.7%

NASDAQ · Mkt cap $2.9 B

RGC fell 22.74% with no news headlines found in the last 48 hours, suggesting the move was driven by either a material event not yet indexed by Yahoo Finance RSS, a technical or sentiment shift, or delayed market reaction to prior information.

No recent news headlines are available to explain the sharp 22.74% decline. RGC is a biotech company listed on NASDAQ, and this class of stock is typically sensitive to clinical trial results, regulatory decisions, funding announcements, or analyst downgrades. The magnitude of the move and its ranking as the 16th biggest loser suggests a material negative catalyst rather than routine volatility. Possible explanations include a negative clinical trial readout, FDA feedback letter, earnings miss, insider selling, short-seller report, or a delayed market reaction to company guidance. Without access to news sources beyond the Yahoo Finance RSS feed provided, the specific catalyst cannot be identified from the available evidence.

RUBI

Rubico IncIndustrials

$0.30−$0.09

-22.5%

NASDAQ · Mkt cap $3.2 M

Rubico announced a reverse stock split on June 23, which typically signals financial distress and often triggers sharp sell-offs as investors reassess the company's fundamentals and dilution risk.

The headline confirms Rubico announced a reverse stock split on June 23, 2026. While the full details are not provided in the excerpt, reverse stock splits are commonly used by companies attempting to maintain minimum exchange listing standards or to reorganize capital structure. These announcements frequently trigger negative market reactions because they are often perceived as a sign of underlying weakness, financial stress, or a precursor to further dilution. Investors may have sold on the news, interpreting the reverse split as a red flag about the company's ability to sustain its stock price through operational performance alone. The 22.53% drop on the day following the announcement is consistent with typical market behavior around such corporate actions, though without visibility into the specific terms, ratio, or company guidance, the full magnitude of negative sentiment cannot be fully attributed to the split alone.

CIIT

Tianci International, Inc.Industrials

$0.69−$0.20

-22.1%

NASDAQ · Mkt cap $3.4 M

Tianci International reported Q2 fiscal 2026 earnings on June 22, likely disappointing the market and triggering the 22% decline two trading days later as investors digested the results.

The company announced financial results for the fiscal quarter ended April 30, 2026 on June 22, 2026. The news headline is truncated and does not provide actual figures, earnings per share, revenue, or guidance commentary that would explain the severity of the selloff. However, the timing is highly suggestive: the earnings announcement came out two business days before the snapshot date, and CIIT ranks as the 18th biggest loser of the day. This pattern is consistent with negative earnings surprises in small-cap logistics stocks, which are sensitive to freight volumes, fuel costs, and container rates. Without access to the actual earnings figures, guidance changes, or management commentary, the specific nature of the miss cannot be confirmed, but the temporal proximity and magnitude of the move strongly implicate the earnings report as the catalyst.

FISN

Deep Fission, Inc.Industrials

$9.76−$2.68

-21.5%

NASDAQ · Mkt cap $461 M

Deep Fission announced a major 18.5 GW customer pipeline on the same day it lost 21.5%, likely because a recent public stock offering on June 22 caused dilution and profit-taking despite the positive pipeline announcement.

Deep Fission released what appears to be positive news—an 18.5 GW customer pipeline—on June 24, yet the stock fell sharply, ranking among the day's biggest losers. The most probable explanation is dilution from the public offering that closed on June 22, two days prior. Secondary offerings often trigger immediate selling pressure as new shares enter circulation and existing shareholders realize gains or reduce exposure. The timing is critical: the company announced positive business development news but the market reacted negatively, suggesting the offering's dilutive effect outweighed the pipeline announcement. It is also possible that the terms of the offering, the number of shares issued, or the offering price relative to the stock's historical levels disappointed investors. Without details on offering size and pricing, the precise magnitude of dilution cannot be calculated, but large public offerings commonly precede multi-day sell-offs in smaller-cap stocks.

DCX

Digital Currency X Technology Inc.Consumer Cyclical

$1.61−$0.43

-21.1%

NASDAQ · Mkt cap $322 M

No news headlines were published in the last 48 hours for Digital Currency X Technology Inc., so the 21% drop cannot be directly attributed to a disclosed event; the decline likely reflects sector-wide crypto weakness, technical selling, or undisclosed developments.

The absence of any news in the Yahoo Finance RSS feed over the past two days means we cannot point to a specific catalyst such as earnings, a product announcement, regulatory action, or corporate guidance. For a small-cap technology stock focused on digital currency, plausible causes include broad cryptocurrency market weakness affecting investor sentiment toward related equities, technical breakdown through a support level triggering algorithmic selling, profit-taking after a prior rally, or negative developments announced through channels not captured in this news feed. Without additional context on the stock's recent trading pattern, insider activity, or sector dynamics on 2026-06-24, the precise trigger remains unclear.

VRXA

Veraxa Biotech Holding AGHealthcare

$2.30−$0.61

-21.0%

NASDAQ · Mkt cap $260 M

VRXA fell 21% despite announcing a positive R&D expansion in Heidelberg on the same day, suggesting the market move was driven by factors unrelated to the headline news—possibly a delayed negative catalyst, sector rotation, or broader biotech weakness.

The provided headlines all describe a facility expansion and pipeline advancement at Veraxa Biotech, which is ordinarily viewed as a constructive development for an early-stage oncology company. Multiple versions of the same expansion announcement were released on June 24, the day of the sharp decline, yet the stock still lost over one-fifth of its value. This disconnect between ostensibly positive operational news and a major sell-off suggests either the market had already priced in the expansion or the decline was triggered by a separate catalyst not captured in these headlines—such as an unannounced clinical setback, insider selling, sector-wide biotech selloff, or negative commentary from an analyst or investor. Without access to concurrent news outside the provided RSS feed, intraday trading data, or broader market conditions on that date, the true driver remains obscured.

VACH

Voyager Acquisition Corp.Financial Services

$2.30−$0.61

-21.0%

AIXI

Xiao-I CorporationTechnology

$2.39−$0.63

-20.9%

NASDAQ · Mkt cap $654 K

No news headlines were found in the last 48 hours for AIXI, so the 20.86% drop likely reflects a delayed announcement, technical selling, broad market pressure on Chinese tech stocks, or untracked company-specific event.

The absence of any news in the Yahoo Finance RSS feed over the past two days means the headline record does not establish a specific catalyst for the sharp 20.86% decline. This is a significant one-day loss for a stock trading at $2.39, suggesting either material news that has not yet reached mainstream financial RSS feeds, or a reaction to events outside the tracked news window. For a Chinese AI-focused company like Xiao-I Corporation, plausible drivers include sector-wide pressure on Chinese tech equities, regulatory concerns specific to AI in China, executive changes or insider transactions, delayed earnings or guidance revision, or forced selling by a major shareholder. Without corroborating headlines, all of these remain inference rather than fact.

XCH

XCHG Limited American Depositary ShareIndustrials

$0.80−$0.21

-20.8%

NASDAQ · Mkt cap $21 M

XCharge announced entry into the energy storage market with its GridOne battery solution on June 23, but the stock fell 20.79% the next day, suggesting investor skepticism about execution, market timing, competitive positioning, or unrelated sector headwinds in battery and EV infrastructure stocks.

The headline documents XCharge's expansion into energy storage and launch of GridOne at EES Europe on June 23, positioning the product for commercial, industrial, and grid applications. However, the stock declined sharply the following day. This disconnect could reflect several scenarios: investors may have judged the announcement as insufficient to offset existing valuation concerns, questioned the company's ability to compete in the crowded energy storage sector, or viewed the diversification as a sign of weakness in core charging business. Alternatively, the decline may be largely unrelated to the news, driven instead by sector rotation away from EV infrastructure stocks, broader market conditions, or a previously scheduled earnings or guidance disappointment that coincided with or preceded the announcement. Without additional context on valuation, prior guidance, or market sentiment shifts, the causality remains ambiguous.

LGHL

Lion Group Holding Ltd.Financial Services

$0.46−$0.12

-20.7%

NASDAQ · Mkt cap $647 K

No news headlines were found in the last 48 hours, so the 20.67% decline cannot be attributed to a specific announced catalyst; the drop likely reflects technical selling, broader market pressure, or unannounced company-specific developments.

The absence of recent headlines makes it difficult to pinpoint a single cause for LGHL's sharp 20.67% drop on June 24, 2026. Lion Group Holding Ltd. is a smaller-cap NASDAQ-listed company, and stocks in this category often experience volatile single-day moves driven by several possible mechanisms: technical liquidation or stop-loss cascades triggered by breach of key support levels, broader sector weakness unrelated to company-specific news, delayed disclosure of negative results or corporate actions not yet picked up by major news feeds, short-covering reversals after a prior run-up, or liquidity constraints typical of lower-priced stocks. Without access to earnings calendar data, insider filings, or company announcements issued directly by LGHL, we cannot confirm which of these hypotheses applies in this case.

RKLX

Daily Target 2X Long RKLB ETF

$32.47−$8.32

-20.4%

NASDAQ

No headlines published in the last 48 hours, but RKLX is a 2X leveraged ETF tracking Rocket Lab (RKLB), so a roughly -10% drop in the underlying stock would mechanically produce this -20% loss through leverage amplification.

The absence of news headlines does not mean no catalyst occurred. RKLX is a daily target 2X long leveraged ETF, meaning it is designed to deliver twice the daily return of its underlying asset, Rocket Lab (RKLB). A -10% move in RKLB would produce approximately -20% in RKLX through the leverage multiplier, which aligns closely with today's -20.4% decline. The actual driver must be a significant move in Rocket Lab itself, which could stem from several categories: a missed earnings or guidance revision from RKLB, a contract win or loss announcement, broader aerospace/space sector weakness, or market-wide risk-off dynamics. Without news coverage of RKLB itself, the root cause remains opaque, though the leveraged structure fully explains RKLX's outsized move relative to what would be typical for a single-stock mover.

VNTG

Vantage CorpIndustrials

$0.65−$0.17

-20.3%

AMEX · Mkt cap $19 M

No news headlines are available for the past 48 hours, so the 20% drop cannot be attributed to a specific announced event; the move likely reflects either a delayed market reaction to earlier news, technical selling, or an undisclosed development in this micro-cap stock.

Vantage Corp traded on the AMEX at $0.65 with a sharp 20% intraday decline and ranked among the day's biggest losers, yet Yahoo Finance returned zero headlines in the preceding 48 hours. This absence of timely news coverage suggests the catalyst is either not yet public, occurred outside the 48-hour window, or is a technical or sentiment-driven move common in sub-dollar stocks. Possible explanations include a delayed market reaction to earlier earnings or guidance, insider selling pressure, a failed financing attempt, deteriorating technical support levels triggering algorithmic selling, or a short-term rumor circulating in lower-liquidity equity channels before mainstream media pickup. Without access to the company's earnings calendar, recent filings, or trading volume data, attributing the move to a specific fundamental driver is not possible.

LNAI

Lunai Bioworks Inc.Healthcare

$3.43−$0.87

-20.2%

NASDAQ · Mkt cap $10 M

No news headlines were found in the last 48 hours, so the 20% drop cannot be attributed to a specific announced event; biotech stocks of this size often trade on clinical trial results, FDA decisions, or funding announcements that may not yet be indexed in major RSS feeds.

The absence of any recent news in the provided sources is striking given the magnitude of the loss. Lunai Bioworks is a smaller-cap biotech name, and a 20% single-day drop of this severity typically reflects a material negative catalyst. Possibilities include an unscheduled clinical trial update, a regulatory setback, loss of funding, insider selling, or a broader sector rotation out of early-stage biotech. It is also possible that news exists but has not yet propagated to the Yahoo Finance RSS feed used here, or that the move was triggered by a private communication (guidance, clinical hold, financing terms) disclosed directly to investors. Without access to the company's website, SEC filings, or real-time news wires, we cannot determine whether this is event-driven or technical in nature.

SRFM

Surf Air Mobility Inc.Industrials

$0.84−$0.21

-20.1%

NYSE · Mkt cap $85 M

No news headlines were found in the last 48 hours to explain Surf Air's 20% single-day drop, leaving the cause unclear without access to delayed reporting, insider activity, or market-wide factors.

Surf Air Mobility is a pre-revenue or early-stage aviation services company, and a 20% intraday decline on the 29th biggest loser list is substantial. With zero news coverage in the provided 48-hour window, the drop was not triggered by a publicly announced earnings report, regulatory action, partnership, or guidance change. For a microcap or small-cap stock like SRFM trading under $1, causes could include sector rotation out of mobility or aviation plays, broader market weakness on the snapshot date, delayed news that hasn't yet appeared in RSS feeds, insider selling, or technical selling if the stock was overbought. Without visibility into broader market conditions or company-specific developments, the driver remains speculative.

CBRS

Cerebras Systems Inc.Technology

$182.26−$44.46

-19.6%

NASDAQ · Mkt cap $44 B

Cerebras fell 19.6% after reporting its first earnings as a public company on June 24, with strong revenue growth but disappointing margin guidance for full-year 2026 that spooked investors despite operational improvements.

Cerebras posted its debut earnings report as a public company on Wednesday, and the market reaction was sharply negative despite mixed fundamentals. Revenue nearly doubled and the company narrowed its quarterly loss to $3.5 million from $44 million a year prior, suggesting operational progress. However, the company guided for lower full-year margins in its data center business, which triggered a sell-off that reached 20% in extended trading and settled near 19.6% by market close. CEO Andrew Feldman attempted damage control by claiming investors "misunderstood" the margin guidance, but the statement came too late to prevent the decline. The stock also faced a broader tech sector headwind on the day. Notably, Cathie Wood's ARK Invest purchased $49 million of Cerebras shares after hours, which may have provided some support to prevent a steeper loss, but failed to reverse the initial earnings-driven decline.

RCT

RedCloud Holdings plcTechnology

$0.51−$0.12

-19.6%

NASDAQ · Mkt cap $15 M

RedCloud announced a $120M India joint venture and expansion into apparel and footwear on the same day the stock dropped 19.6%, suggesting market disappointment with deal terms, valuation, or execution risk despite the headline appearing positive.

The timing is striking: RedCloud released what reads as a growth announcement (a twenty-year license agreement for Asia expansion and category diversification) and the stock fell sharply. This disconnect suggests the market's interpretation differed from the press release framing. Possible explanations include concern that the $120M valuation or revenue split favors the joint venture partner over RedCloud, doubt about monetization timelines in those categories, dilution from equity issuance to fund the deal, or general skepticism about execution risk in a new geography. Alternatively, the stock may have been technically extended and the news provided a trigger for profit-taking or short covering. Without access to deal specifics, guidance context, or analyst commentary, we cannot confirm which factor drove the sell-off.

HYLN

Hyliion Holdings Corp.Consumer Cyclical

$4.92−$1.18

-19.3%

AMEX · Mkt cap $654 M

Hyliion shares crashed 19.34% after short-seller Pelican Way Research published a report on June 23 alleging that the company's $133 million AI data center deal with VFG Tech Holdings is fraudulent, labeling it a "sham."

The headline evidence directly points to a short-seller attack as the primary catalyst. Pelican Way Research issued a critical report questioning the legitimacy of Hyliion's marquee $133 million letter of intent with VFG Tech Holdings, characterizing the deal as fake or misleading. This is a material allegation because major partnerships and revenue-generating agreements are typically core to an early-stage or turnaround company's narrative and valuation. Short-seller reports often trigger sharp selloffs as they raise reputational and fundamental questions that investors rush to reprice. The timing aligns precisely with the stock's worst day in a year, as noted in the headline. No offsetting positive news or earnings data has been provided to counteract this negative catalyst. The second headline about Visteon is unrelated to Hyliion and appears to be a generic market snippet.

YYGH

YY Group Holding LimitedIndustrials

$1.72−$0.41

-19.2%

NASDAQ · Mkt cap $4.5 M

No news headlines were found in the last 48 hours to explain YYGH's 19.25% decline, leaving the specific catalyst unclear without additional information.

YY Group Holding Limited dropped nearly 20% on June 24, 2026, but no corresponding news items appeared in the Yahoo Finance RSS feed during the preceding 48 hours. This disconnect suggests either that relevant news broke outside the monitored feed window, that the market reacted to a delayed announcement, or that the move was driven by factors unrelated to company-specific developments. YYGH operates in the live streaming and social entertainment space, a sector sensitive to regulatory shifts in China, licensing disputes, platform policy changes, and broader tech valuations. For stocks in this space, typical catalysts include competitive pressure, user growth disappointment, advertiser pullback, or geopolitical concerns affecting Chinese tech assets. Without actual news, the specific trigger cannot be identified from available evidence.

MST

Leveraged Long + Income MSTR ETF

$8.69−$2.07

-19.2%

NASDAQ

No news headlines were published in the last 48 hours, so the 19.23% drop cannot be directly attributed to a company announcement. The decline likely reflects weakness in the underlying Bitcoin price or broader crypto asset volatility, since MST is a leveraged long Bitcoin ETF.

MST is a leveraged long Bitcoin ETF with income strategies, meaning it amplifies daily moves in Bitcoin's price. With no news headlines available to explain the stock-specific move, the most probable cause is a significant decline in Bitcoin itself over the past 24 hours. Leveraged ETFs magnify their underlying asset's performance by 2x or 3x (depending on the fund structure), so a roughly 9–10% drop in Bitcoin would produce a roughly 18–20% decline in the leveraged fund. This is a structural feature of the security, not a failure of management or operations. Alternative possibilities include broader cryptocurrency market stress, regulatory concerns affecting digital assets, or technical selling pressure in the crypto space, but without headline confirmation, these remain inference only.

MNY

MoneyHero Limited Class A Ordinary SharesCommunication Services

$0.96−$0.23

-18.9%

NASDAQ · Mkt cap $40 M

MoneyHero reported 15% revenue growth and strong operational results on June 24, yet the stock fell 18.92%, suggesting the market either anticipated higher growth, has concerns about profitability or cash burn despite efficiency gains, or is responding to forward guidance or regional headwinds no…

The company announced Q1 2026 results showing 15% year-over-year revenue growth to $16.5 million, with higher-margin Wealth and Insurance revenue growing 31% and now representing over 28% of total revenue. The earnings call highlights emphasize strong top-line growth and operational efficiencies. However, the 18.92% single-day drop despite positive headline metrics suggests investors either expected stronger growth, are concerned about absolute profitability levels, margin sustainability, or cash runway, or reacted negatively to forward guidance or commentary about challenges in Taiwan and the Philippines mentioned in the call highlights. Without access to full guidance, net income figures, or analyst consensus, the specific disappointment cannot be pinpointed, but the disconnect between growth metrics and stock reaction indicates either unmet expectations on the bottom line or macroeconomic/regional risks that outweighed top-line strength.

MSTX

Daily Target 2X Long MSTR ETF

$9.01−$2.08

-18.8%

NASDAQ

No news headlines were published in the last 48 hours, but MSTX is a 2X leveraged long ETF on MicroStrategy stock, so the -18.76% drop likely reflects a sharp decline in the underlying MSTR shares, amplified by the fund's 2X daily reset mechanism.

The absence of any news in the provided headlines makes it impossible to identify a specific catalyst for today's move. However, MSTX's structure itself offers the most plausible explanation: as a daily 2X leveraged long ETF tracking MicroStrategy (MSTR), it amplifies both gains and losses in the underlying stock. A roughly -9% to -10% move in MSTR would produce the observed -18.76% decline in MSTX after accounting for expense ratios and the mechanics of daily rebalancing. Without access to intraday MSTR price data or real-time news, the root cause of the underlying MicroStrategy decline remains unknown. Possible categories include Bitcoin price weakness, broader tech sector selloff, company-specific news not yet syndicated to Yahoo Finance, or technical selling, but these are speculative.

MSTP

GraniteShares 2x Long MSTR Daily ETF

$13.68−$3.14

-18.7%

NASDAQ

No headlines were available in the last 48 hours, but MSTP is a 2x leveraged ETF tracking MicroStrategy (MSTR), so a significant drop in MSTR stock would directly amplify into an 18.69% loss for this fund.

MSTP is a daily reset leveraged ETF designed to deliver twice the daily return of MSTR. With no news headlines provided in the last 48 hours, we cannot identify a specific catalyst from company announcements or market events. However, the structure of this security itself offers a clear explanation: if MSTR dropped approximately 9-10% today, MSTP would fall roughly double that due to its 2x leverage. MSTR is a bitcoin-proxy stock highly sensitive to cryptocurrency price swings, macro risk-off sentiment, and volatility. The 18.69% decline likely reflects either a sharp drop in MSTR shares themselves or compounding effects from daily rebalancing during a volatile period. Without actual news, the most probable cause categories are a significant move in Bitcoin, broader equity selloff, or firm-specific MSTR news not yet captured in the news feed provided.

CRE

Cre8 Enterprise Limited Class A Ordinary SharesIndustrials

$3.22−$0.74

-18.7%

NASDAQ · Mkt cap $5.2 M

CRE fell 18.69% on June 24 with no news headlines found in the last 48 hours, making the specific catalyst unclear; the move likely reflects either technical/market sentiment pressure, a delayed corporate announcement, or sector headwinds not yet reflected in available news.

No recent news headlines were available to explain CRE's sharp 18.69% single-day decline. This absence of obvious catalysts leaves several hypotheses open. The stock could be reacting to broader market conditions, sector rotation, or technical selling pressure that accumulates without explicit company news. Alternatively, a material corporate announcement—earnings miss, guidance cut, leadership change, regulatory setback, or capital structure event—may have occurred but not yet appeared in Yahoo Finance RSS feeds or may have been released after market close on the prior trading day. Small-cap stocks like CRE can also experience outsized moves on low volume or following after-hours news that bleeds into the next session's open. Without access to the company's investor relations releases, SEC filings, or real-time trading data, pinpointing the trigger requires additional sources.

BWET

Breakwave Tanker Shipping ETF

$167.55−$38.26

-18.6%

AMEX

No news headlines from the past 48 hours were found, but BWET's 18.6% drop likely reflects a sharp decline in tanker shipping rates or a broader market selloff in the shipping sector, as this ETF is highly sensitive to freight pricing dynamics.

The absence of any news headlines in the provided data makes it impossible to confirm a specific catalyst for today's decline. However, BWET is a tanker shipping ETF whose price tracks the underlying earnings and valuations of container and tanker shipping companies, which are themselves tied to global freight rates, fuel costs, and shipping demand. A collapse in tanker rates or negative macroeconomic signals affecting global trade would typically trigger a sharp drop in this security. Alternatively, the move could reflect delayed reaction to weekend news not yet captured in the RSS feed, technical selling, or broader weakness in cyclical equities. Without access to shipping rate data or market-wide context for June 24, 2026, the specific driver cannot be isolated from the available evidence.

WHLR

Wheeler Real Estate Investment Trust, Inc.Real Estate

$2.43−$0.54

-18.2%

NASDAQ · Mkt cap $942 K

Wheeler Real Estate filed a regulatory notice about marketing 35 properties for sale, signaling a potential portfolio liquidation or restructuring that likely triggered the 18% single-day decline as investors reacted to dilution or distress signals.

The Yahoo Finance headline indicates that WHLR filed a regulatory disclosure regarding the marketing of 35 properties, a material action for a real estate investment trust. The headline cuts off mid-sentence, but the context of a REIT suddenly putting significant real estate assets on the market typically signals either a liquidity crisis, capital restructuring, or strategic pivot. For a smaller REIT trading at $2.43, the sale or marketing of 35 properties represents a substantial portion of potential operating assets and would raise concerns among shareholders about management's confidence in hold-to-maturity strategy, dilution risk if equity is used to fund operations, or deteriorating fundamentals forcing asset sales. The magnitude of the decline (rank 40 biggest loser) and speed (18% in one day) align with a market reaction to an unexpected or unfavorable disclosure rather than a rumor, though without the full text of the filing it is impossible to confirm exact details.

GLGG

Leverage Shares 2x Long GLXY Daily ETFFinancial Services

$8.43−$1.86

-18.0%

CHPT

ChargePoint Holdings, Inc.Consumer Cyclical

$5.58−$1.21

-17.8%

NYSE · Mkt cap $160 M

ChargePoint fell 17.76% on June 24 after UBS maintained a Neutral rating on June 23, citing ongoing cash burn and policy headwinds affecting the EV charging provider.

The June 23 UBS note maintaining a Neutral rating appears to be the primary catalyst for the sharp decline. UBS's specific concerns about cash burn and policy headwinds are material for a capital-intensive infrastructure company dependent on government subsidies and EV adoption trends. The timing of the 10.8% afternoon drop on June 23 following the UBS call aligns with the broader 17.76% loss by June 24 close, suggesting the negative analyst sentiment and reiteration of risk factors drove the selling. A June 24 article noting CHPT as a broker-favored stock despite market turmoil came after the damage was done, indicating the UBS downside view outweighed any positive screening metrics. For EV charging infrastructure plays, analyst commentary on cash runway and policy uncertainty typically moves shares sharply, as investor confidence hinges on subsidies and charging network expansion viability.

CNTN

Canton Strategic Holdings IncHealthcare

$2.67−$0.57

-17.5%

NASDAQ · Mkt cap $157 M

Canton Strategic Holdings fell 17.49% on June 24, likely driven by profit-taking or broader market sentiment rather than negative news, as the company announced a new locking service to support network infrastructure on June 23.

The only headline provided is a June 23 announcement of a locking service launch to support Canton Network infrastructure providers. This is a product development announcement, not typically a catalyst for a sharp single-day decline. The timing suggests the news may have been released after market close or that investors initially reacted negatively to the announcement itself, viewing it as insufficiently material or strategically significant. Alternatively, the decline may reflect profit-taking following a run-up, profit-taker rotation, or unrelated market headwinds affecting NASDAQ-listed blockchain or fintech-adjacent companies. Without additional context on the stock's recent performance, sector momentum, or broader market conditions on June 24, the precise trigger remains unclear. The news does not establish a negative catalyst. insufficient_data

DMIIR

Drugs Made In America Acquisition II Corp.

$0.07−$0.02

-17.4%

NASDAQ

No news headlines were published in the last 48 hours explaining the 17.39% drop in DMIIR. The decline likely reflects either a broad sell-off in blank-check companies, deteriorating merger prospects, or an undisclosed development in the acquisition process.

DMIIR is a Special Purpose Acquisition Company (SPAC), and the stock's steep decline with zero news coverage in the past two days suggests the catalyst may be indirect or already priced in from earlier reports. SPAC stocks are particularly sensitive to changes in merger timelines, regulatory hurdles, or funding conditions. The lack of any recent headline also raises the possibility that negative news circulated through investor networks or company filings before being picked up by major financial media, or that the decline reflects a technical sell-off or broader sector rotation away from blank-check entities. Without identifying headlines, the most probable categories of cause are either an acquisition update that disappointed markets or a general de-rating of SPAC risk appetite in the broader market.

MNDR

Mobile-health Network Solutions Class A Ordinary SharesHealthcare

$0.47−$0.10

-17.3%

NASDAQ · Mkt cap $2.0 M

Mobile-health Network Solutions announced a partnership expansion into cybersecurity with Skylink-Contfinity to serve Singapore clinics, but the stock fell 17.25% anyway, suggesting the market either viewed the partnership as insufficient growth or reacted to other undisclosed factors.

The company issued a press release on June 23-24 announcing a strategic partnership with Skylink Innovations and Contfinity to launch the OtterSG bundled solution targeting over 2,400 clinics in Singapore. This is nominally positive news representing geographic and product-line expansion. However, the stock dropped sharply on the announcement date, which is counterintuitive. One possibility is that investors expected larger or more transformative news and viewed this partnership as incremental rather than material. Another is that the market has concerns about Mobile-health's core business trajectory or valuation that overshadow partnership announcements. A third is that the stock is sensitive to technical factors, short covering, or sector headwinds unrelated to this specific news. The stock's low price of $0.47 and its rank as the 45th biggest loser suggests broader selling pressure rather than a targeted negative catalyst tied to the partnership itself.

RCAX

Daily Target 2X Long RCAT ETF

$4.75−$0.98

-17.1%

NASDAQ

No news headlines appeared in the last 48 hours; the 17% decline in this 2X leveraged ETF likely reflects a sharp drop in its underlying RCAT index or broad market weakness on June 24th that amplified through the leverage mechanism.

RCAX is a daily target 2X long leveraged ETF tracking RCAT. Without any news headlines to explain the move, the decline is most likely attributable to two structural factors. First, leveraged ETFs amplify intraday or daily moves in their underlying index by a fixed multiple, so a 9% underlying decline would produce roughly an 18% fund decline, consistent with the observed 17% drop. Second, leveraged ETFs experience decay over longer holding periods due to their daily rebalancing mechanism, though that is typically a slower effect. The absence of news suggests either the underlying index RCAT experienced a significant sell-off on June 24th due to market-wide factors, sector weakness, or technical/algorithmic trading, or no material company-specific or sector event was announced. Without visibility into RCAT composition or June 24th market conditions, the precise trigger remains unclear.

CXAI

CXApp Inc.Technology

$0.18−$0.04

-17.0%

NASDAQ · Mkt cap $10 M

No news headlines were found in the last 48 hours, so the cause of the 16.96% drop cannot be directly attributed to a specific public event. The decline may reflect broader market sentiment, technical selling, or undisclosed company-specific factors.

Without any recent news coverage, the cause of CXAI's sharp 16.96% decline remains unclear from public information. For a micro-cap stock trading at $0.18, typical catalysts for single-day losses include delayed earnings or guidance announcements, insider selling or lock-up expirations, short-seller reports or negative social media momentum, sector rotation out of technology or growth stocks, or technical breakdown through support levels that trigger algorithmic selling. Alternatively, the stock may have gapped down on news that has not yet been indexed by Yahoo Finance RSS, or the move could reflect pre-market or after-hours developments. Without access to Level 2 order flow or company filings from today, it is not possible to determine which of these scenarios applies.

RGTX

Daily Target 2X Long RGTI ETFFinancial Services

$19.17−$3.80

-16.5%

IREG

Leverage Shares 2x Long IREN Daily ETF

$15.90−$3.12

-16.4%

NASDAQ

No news found in the last 48 hours to explain the 16.43% drop, but IREG is a 2x leveraged long ETF on IREN, so the underlying stock likely fell roughly 8% today, which this ETF amplifies mechanically.

Zero news headlines are available in the provided timeframe, so there is no direct evidence of a catalyst. However, IREG is a leveraged derivative product—a 2x long daily ETF tracking IREN—meaning its price moves are mechanically amplified versions of the underlying stock's movement. A 16.43% drop in IREG is consistent with an approximately 8% decline in IREN itself, amplified by the leverage factor plus any tracking decay from daily rebalancing. Without access to IREN's own news or price action, the actual cause of the underlying move remains unknown. It could reflect company-specific news on IREN (earnings, guidance, operational announcement), sector rotation, or technical selling. Leveraged ETFs are also sensitive to intraday volatility, which can compound losses on down days independently of underlying fundamentals.

IRE

Defiance Daily Target 2X Long IREN ETF

$20.67−$4.03

-16.3%

AMEX

No news headlines were found in the last 48 hours, but this is a 2x leveraged long ETF on IREN, so a sharp market-wide or IREN-specific selloff would amplify any underlying decline roughly twofold.

The absence of company-specific news in the last 48 hours suggests the move is not driven by a discrete corporate event. However, IRE is a daily target 2x leveraged long ETF tracking IREN, which means it amplifies both gains and losses in its underlying stock. A 16.32% drop in a leveraged ETF typically reflects either a significant decline in the underlying security or broader market weakness hitting growth or speculative names. Leveraged ETFs are also subject to daily rebalancing drag in volatile markets, which can contribute to underperformance. Without visibility into IREN's price action or the broader market on June 24, 2026, the most likely explanations are either a sharp move down in IREN itself or sector-wide selling that disproportionately hit the underlying holding.